View Post

Practicing Outside the Pharma Box in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Dawn Fallik From: onclive.com When Martine Piccart, MD, PhD, was a child, she sometimes watched her father, a gynecologist, talk to his patients. She remembers his respect for them and their families and the way he communicated, focusing on the positive but not shying away from delivering bad news. “He always took the time to explain in detail not …

View Post

Gut microbe may promote breast cancers

In Clinical Trials by Barbara Jacoby

Source: Johns Hopkins Medicine From: eurekalert.org Short-term exposure to B. fragilis toxin leaves lasting impression in cells, increasing the risk for cancer A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns …

View Post

Quantitative Transmission Ultrasound Research Shows Better Performance than Mammography

In Clinical Trials by Barbara Jacoby

From: PR Newswire First-in-class, first-in-human study compares new breast imaging modality to digital mammography QT Imaging™, developers of the FDA-cleared QTscan®, has completed a first-in-class and first-in-human study of transmission ultrasound as a new imaging technology for breast health screening. The recently published study in Academic Radiology found that, compared to full-field digital mammography (FFDM), transmission ultrasound showed increased sensitivity, …

View Post

FDA grants fast track designation to ARX788 for breast cancer subset

In In The News by Barbara Jacoby

Source: HemOnctoday From: healio.com The FDA granted fast track designation to ARX788 as monotherapy for certain patients with HER2-positive breast cancer. The designation applies to use of the agent for patients with advanced or metastatic disease who received at least one prior anti-HER2-based regimen in the metastatic setting. ARX788 (Ambrx) — an antibody-drug conjugate that targets the HER2 receptor — …

View Post

New breast cancer drug shows promise, boosts the body’s ability to destroy tumors

In Clinical Trials by Barbara Jacoby

By: Study Finds From: studyfinds.org A signaling pathway in the body that helps fight off infections may also hold the key to a breakthrough in breast cancer research. Researchers from the University of North Carolina say activating this path can allow genetically engineered cells destroy breast cancer tumors in mice. Their study finds this immunotherapy activates the “STING” pathway, an …

View Post

Most breast cancer patients satisfied ‘going flat’ after mastectomy

In In The News by Barbara Jacoby

By: Chris Melore From: studyfinds.org A mastectomy can be a life-changing decision for women dealing with or at high-risk for breast cancer. While many women opt for breast reconstruction, a new study finds more women are “going flat” after surgery. Researchers from UCLA say although most of these women are happy with their choice, nearly a quarter feel unsupported by …

View Post

Alpha-TEA helps with breast cancer

In Clinical Trials by Barbara Jacoby

By: Christina Burkhart From: abc12.com One in eight women will be diagnosed with breast cancer at some point in her lifetime. One in four of those breast cancer diagnosis will be HER-2-positive. It’s an aggressive form of breast cancer and is more likely to recur than HER2-negative breast cancer. Now a new trial is underway to stop this cancer in …

View Post

Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study

In Clinical Trials by Barbara Jacoby

From: docwirenews.com ABSTRACT Breast-conserving therapy was once a contraindication in young breast cancer patients (aged ≤40 years). Emerging studies suggest that breast-conserving therapy and mastectomy could achieve similar prognosis in this population. However, the effect of molecular subtype disparity on surgical strategy in these patients remains unclear. Data from 8656 young patients (aged ≤40 years) diagnosed with invasive breast cancer …

View Post

Your Cancer Answers: Which genetic syndromes increase the risk of breast cancer?

In In The News by Barbara Jacoby

By: Dr. Kevin Lin  From: lompocrecord.com Question: Which genetic syndromes increase the risk of breast cancer? Many risk factors for breast cancer have been identified, including genetic, environmental, and lifestyle factors. Some are modifiable and others are not. A family history of breast cancer in a first-degree relative is the most widely recognized breast cancer risk factor, but only 5-10% …